No Data
Poinsettia: 2024 performance forecast
Involved in the "first major bidding case of national procurement", ApicHope Pharmaceutical may face its first loss after going public | Interpretations
① Due to the continued increase in research and development investment, reimbursement of medical insurance refunds, and other factors, ApicHope Pharmaceutical may experience its first loss since its listing in 2024. ② It is expected that the net loss in Q4 will be between 0.225 billion yuan and 0.433 billion yuan.
ApicHope Pharmaceutical (300723.SZ) announces a预亏, expecting a net loss of 0.472 billion yuan to 0.68 billion yuan for the fiscal year 2024, turning from profit to loss.
ApicHope Pharmaceutical (300723.SZ) released its performance forecast for 2024, predicting that the annual net profit attributable to shareholders will be...
Overview of the lifting of restrictions on the circulation of A-share stocks | January 17.
According to the Zhitong Finance APP, on January 17th, 12 listed companies had their restricted shares released, with a total market value of approximately 9.663 billion yuan. The specific details of the restricted share release today are as follows: Stock abbreviation Stock code Restricted share type Released share quantity Pangang Group Vanadium & Titanium Resources 000629 Stock-based Incentive 3.9867 million Harbin Electric Corporation Jiamusi Electric Machine 000922 Stock-based Incentive 2.34 million NARI Technology 600406 Stock-based Incentive 11.883 million Lanzhou Banks 001227 Pre-issue shares 2.85 billion Shenzhen Jieshun Science And Technology Industry 002609 Stock-based Incentive 0.1936 million Shanghai Yaoji Technology 0
ApicHope Pharmaceutical (300723.SZ): Wholly-owned subsidiary has obtained the registration certificate for Amlodipine Besilate Tablets.
On January 14, Gelonghui reported that ApicHope Pharmaceutical (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Amlodipine Besylate Tablets.
Is ApicHope Pharmaceutical (SZSE:300723) Using Too Much Debt?
Do ApicHope Pharmaceutical's (SZSE:300723) Earnings Warrant Your Attention?
